Introduction
============

Chronic hepatitis C virus (HCV) infections affect approximately 130-170 million people worldwide and are associated with a greatly increased risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) [@B1], [@B2]. Dysfunction of virus-specific CD8^+^ cells was demonstrated to be a fundamental property of persistent viral infections, such as HCV [@B3], [@B4]. In chronic viral infection, the persistent exposure to high concentrations of viral antigens leads to various degrees of T-cell functional impairments called T-cell exhaustion [@B5]-[@B7]. Previous studies have indicated that the interaction between programmed cell death-1 (PD-1) and its ligands plays a critical role in T-cell exhaustion [@B8]. PD-1 has been shown to be upregulated in HCV-specific CD8^+^ cells, indicating that PD-1 upregulation may be an essential mechanism for viral immune escape in chronic HCV infections [@B9]-[@B11].

PD-1 is a key immune-checkpoint receptor expressed by activated T cells, B cells, and myeloid cells, and it delivers inhibitory signals by interacting with its two major ligands: programmed cell death ligand-1 (PD-L1) and -2 (PD-L2) [@B12]. PD-L1 (B7-H1) is largely expressed in both hematopoietic and parenchymal cells, and PD-L2 (B7-DC) is mainly expressed in macrophages and dendritic cells [@B13]. In tumor tissues, activated T cells can encounter the immunosuppressive PD-L1 and PD-L2, and both ligands are expressed by tumor cells and microenvironment, as described for lymphoproliferative diseases [@B14]. Recent studies have shown that antibody-mediated interference with PD-1 caused the regression of several tumor types, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer, in some patients [@B3]. The expression of PD-L1 is induced by inflammatory cytokines, such as interferon (IFN)-γ or interleukin-10 [@B16]. Moreover, it has been shown that a soluble form of PD-L1 (sPD-L1) can be detected in the sera of patients, which correlates with the amount of PD-L1 expressing cells [@B16].

An increase of sPD-L1 was reported in patients with malignancies, including multiple myeloma (MM) [@B17], RCC [@B18], and diffuse large B-cell lymphoma (DLBCL) [@B12]. Moreover, a recent study showed that a high sPD-L1 level was a possible prognostic indicator for a poor outcome in hepatocellular carcinoma (HCC) patients [@B15]. Although the PD-1/PD-L1 inhibitory pathway was shown to be associated with the T-cell dysfunction seen in chronic HCV infection [@B3], the involvement of sPD-L1 in the immunopathogenesis of CHC has yet to be determined. Therefore, we hypothesized that the level of sPD-L1 might be associated with clinical features, such as the severity of inflammation, the progression of fibrosis, carcinogenesis, and especially the efficacy of treatment including IFN-α, which has been shown to induce the expression of PD-L1, in patients with CHC.

Before the introduction of direct-acting antiviral agents (DAA), pegylated IFN (PegIFN)-α and ribavirin (RBV) were the standard treatments for HCV genotype 1 infections. However, with the approval of telaprevir (TVR), an HCV non-structural 3/4A (NS3/4A) protease inhibitor, the TVR-based triple therapy has led to an improved sustained virological response (SVR) rate compared with PegIFN-α monotherapy and PegIFN-α plus RBV dual therapy [@B19], [@B20]. However, the TVR-based triple therapy is associated with an increased severity and rate of adverse events, including skin rash, pruritus, anemia, and anorectal diseases [@B20], [@B21]. Simeprevir (SMV) is a second-generation oral HCV NS3/4A protease inhibitor with antiviral activity against HCV genotype 1, 2, 4, 5, and 6 infections [@B22]. The SMV-based triple therapy showed a favorable efficacy without inducing severe dermatologic and hematologic toxicities [@B23]. In the present study, we aimed to determine whether the sPD-L1 levels in patients with CHC were associated with clinical features of the disease and the efficacy of TVR- and SMV-based triple therapies, including IFN-α. Moreover, the expression of PD-L1 in hepatocytes was examined after stimulation with IFN-γ.

Methods
=======

Patients
--------

This study enrolled two groups of 40 HCV genotype 1b Japanese patients who received 12 weeks of TVR-based or SMV-based triple therapies, followed by a 12-week dual therapy that included PegIFN-α and RBV. The median age was 63 years (range: 28-84 years). Twenty-two patients with chronic hepatitis B (CHB) (11 male and 11 female, median age 57 (30-76) years) and 10 healthy donors (5 male and 5 female, median age 64 (50-71) years) were used as controls. Serum samples were collected from each patient or healthy donor.

According to the prior treatment response, relapse was defined as undetectable HCV during and at the end of treatment, with HCV RNA positivity occurring later. A non-responder was defined as detectable HCV RNA for more than 24 weeks. Patients with decompensated liver cirrhosis, HCC, co-infection with hepatitis B virus or human immunodeficiency virus, autoimmune hepatitis, primary biliary cholangitis, hemochromatosis, or Wilson\'s disease were excluded from the study. Patients with uncontrollable hypertension or diabetes mellitus, chronic renal failure, depression, and those with a history of alcohol abuse, were also excluded. Information regarding the patient profiles is shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

Study design
------------

All patients received a 12-week triple therapy that included either TVR \[1500 or 2250 mg/day; the initial dose of TVR was determined by each attending physician based on each patient\'s baseline characteristics such as bodyweight (BW)\] (Telavic; Mitsubishi Tanabe Pharma, Osaka, Japan) or SMV (100 mg/day) (Sovriad; Janssen Pharmaceutical K.K., Tokyo, Japan) combined with PegIFN-α2a (180 μg/week) (Pegasys; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) or PegIFN-α2b (1.5 μg/BW kg/week) (Peg-Intron; MSD, Tokyo, Japan) and RBV (600-1000 mg/day according to BW as follows: \<60 kg: 600 mg/day; 60-80 kg: 800 mg/day; and \>80 kg: 1000 mg/day; if the patient\'s hemoglobin was \<13 g/dL at the start of therapy, RBV was reduced by 200 mg) (Copegus; Chugai Pharmaceutical Co., Ltd. or Rebetol; MSD) and followed by a 12-week dual therapy that included PegIFN-α2a or PegIFN-α2b and RBV.

This study was conducted in accordance with the Declaration of Helsinki. The study was reviewed and approved by the Niigata University Medical and Dental Hospital Institutional Review Board. Written informed consent was obtained from all of the individuals who enrolled in the study according to the institutional review board\'s approved protocols (approval no. 1474) at the Niigata University Medical and Dental Hospital.

Laboratory and safety assessments
---------------------------------

Laboratory and safety assessments were performed at treatment initiation; at treatment weeks 2, 4, 8, 12, 16, 20, and 24; at the end of treatment; and at 12 and 24 weeks after the end of treatment. Data on adverse events were collected, and physical examinations were performed at each visit if they were clinically indicated.

Determination of HCV markers
----------------------------

The baseline and follow-up tests for HCV viremia were performed using a real-time polymerase chain reaction (PCR) assay (COBAS TaqMan HCV test, Roche Diagnostic, Tokyo, Japan) with a lower limit of quantitation of 15 IU/mL and a linear dynamic range of 1.2-7.8 log IU/mL. The core amino acid substitutions at positions 70 and 91 of the HCV genome were determined by direct sequencing, as reported previously [@B24].

Efficacy of treatment
---------------------

Successful treatment was SVR, which was defined as undetectable serum HCV RNA 24 weeks after the end of treatment. Early virological response during the first 12 weeks of treatment was categorized as follows: rapid virological response (RVR), undetectable HCV RNA at week 4; complete early virological response (cEVR), undetectable at week 12. The end of treatment response (ETR) was defined as undetectable HCV RNA at the end of treatment. Relapse was defined as a response that was an ETR but non-SVR.

Interleukin 28B single-nucleotide polymorphism
----------------------------------------------

Human genomic DNA was extracted from the peripheral blood. Single-nucleotide polymorphism (SNP) genotyping of the interleukin 28B (IL28B) (rs8099917) gene was performed using the TaqMan Allelic Discrimination Demonstration Kit (7500 Real-time PCR System) (Applied Biosystems, Foster City, CA, USA). The rs8099917 genotype was classified into the following 2 categories: TT (major genotype) and non-TT (minor genotype, TG or GG).

Measurement of serum sPD-L1
---------------------------

Serum levels of sPD-L1 were examined using a specific enzyme-linked immunosorbent assay (ELISA) kit from Cusabio Biotech (Wuhan, China) according to the manufacture\'s protocol. Each sample was tested in duplicate. The detection limits for ELISA was 3.9 pg/ml.

Cell surface expression of PD-L1 on human hepatocytes
-----------------------------------------------------

Immortalized human hepatocytes (HPT1) were kindly provided by Prof. T. Kanda at Chiba University, Chiba, Japan. Cell surface expression of PD-L1 was examined using flow cytometry before and after stimulation with IFN-γ. Cells (10^5^) were labeled with anti-PD-L1 (CD274)-PE and anti-MHC class I-FITC antibodies at 4°C for 30 min in darkness, and the cells were washed 2 times and measured with a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA). Data were analyzed using Flow Jo software (Tree Star Inc., Ashland, OR, USA). Expression of the mRNA of PD-L1 was also examined with real-time qPCR.

Statistical analysis
--------------------

Continuous data from patients are expressed as the median with the interquartile range. The significance of differences was analyzed statistically with the Chi-square, Fisher\'s exact test, or the Mann-Whitney U test, as appropriate, using SPSS software (Ver.18, SPSS Inc., Chicago, IL, USA). Correlations between parameters were determined by linear regression analysis. In all cases, the level of significance was set as *P* \<0.05.

Results
=======

Patient characteristics
-----------------------

The patient characteristics in the CHC, CHB, HC, TVR, and SMV groups are summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The analysis of the pretreatment factors revealed that serum asparate aminotransferase (AST), alanine aminotransferase (ALT), and alpha-fetoprotein (AFP) in the patients with CHC were significantly high compared with HC, although there were no significant differences in the serum ALT levels between the patients with CHC and CHB (Table [1](#T1){ref-type="table"}). Among the patients with CHC, the baseline hemoglobin level and the number of patients infected with HCV with a mutation at position 91 of the HCV core protein were significantly higher in the TVR group compared with the SMV group (*P* = 0.034 and 0.012, respectively), but there was no significant difference in the other examined factors between the TVR and SMV groups (Table [2](#T2){ref-type="table"}).

Treatment responses
-------------------

Treatment tolerability is summarized in Table [3](#T3){ref-type="table"}. Adverse events resulted in treatment discontinuation in 20% (8/40 cases) and 2.5% (1/40 cases) of patients in the TVR and SMV groups, respectively (*P* \<0.001). Eight patients (20%) discontinued TVR because of adverse events (four patients experienced skin rash, three patients experienced anemia, and one patient experienced renal dysfunction). Although the cumulative exposure to RBV for the whole 24-week treatment period (as a percentage of the target dose) was significantly lower in the TVR group than the SMV group (75.9 ± 24.7% vs. 92.1 ± 28.0%, *P* = 0.007), cEVR, ETR, and SVR did not significantly differ between the TVR and SMV groups (92.5% vs. 97.5%, 92.5% vs. 92.5%, and 85.0% vs. 80.0%, respectively) (Figure [1](#F1){ref-type="fig"}). The rate of patients achieving RVR was significantly lower in the TVR group than in the SMV group (60.0%vs. 92.5%, *P* = 0.001), but the lower RVR rate did not seem to affect the SVR rate.

Serum sPD-L1 and correlation with clinical characteristics
----------------------------------------------------------

The pretreatment serum sPD-L1 levels were significantly increased in patients with CHC (median 109.3 pg/ml, range 23.1-402.3) compared with patients with CHB (69.2 pg/ml, 15.5-144.8; *P* \<0.001) and HC (100.3 pg/ml, 40.1-166.6; *P* = 0.039) (Figure [2](#F2){ref-type="fig"}). The pretreatment level of sPD-L1 was positively correlated with the AST and ALT levels in patients with CHC (R^2^ = 0.066, *P* = 0.032, and R^2^ = 0.082, *P* = 0.016, respectively) (Figure [3](#F3){ref-type="fig"}AB). There was no significant correlation between serum sPD-L1 and platelet levels (Figure [3](#F3){ref-type="fig"}C), but serum sPD-L1 was also significantly correlated with the AFP levels (R^2^ = 0.149, *P* = 0.002) (Figure [3](#F3){ref-type="fig"}D). Although the pretreatment levels of serum sPD-L1 were not significantly different between the patients who achieved SVR (105.0 pg/ml, 23.1-402.3) and non-SVR (133.5 pg/ml, 39.9-187.2) (*P* = 0.391) (Figure [4](#F4){ref-type="fig"}), these results indicated a correlation between the severity of inflammation and sPD-L1 levels in patients with CHC.

Induced expression of PD-L1 on hepatocytes
------------------------------------------

It has been demonstrated that the existence of sPD-L1 was associated with PD-L1 expression on the cell surface. To examine the expression of PD-L1 on the cell surface of hepatocytes, we used immortalized hepatocytes (HPT1) (Figure [5](#F5){ref-type="fig"}). The hepatocytes did not express PD-L1 without any stimulation. However, IFN-γ clearly induced the expression of PD-L1 on the hepatocytes (Figure [5](#F5){ref-type="fig"}A). We also confirmed the induction of PD-L1 mRNA in the hepatocytes with IFN-γ (Figure [5](#F5){ref-type="fig"}B). Considering the significant positive correlation between the sPD-L1 and aminotransferase levels, these results revealed that sPD-L1 was released from the hepatocytes and that the increase in sPD-L1 resulted from the induction of PD-L1 expression on the hepatocytes due to inflammatory cytokines, including IFN-γ.

Discussion
==========

In the present study, we investigated the sPD-L1 levels in the sera of 80 Japanese patients with chronic genotype 1b HCV infection. We found that the pretreatment sPD-L1 levels were significantly increased in patients with CHC compared with patients with CHB and healthy controls. To the best of our knowledge, this is the first study that revealed an increase in serum sPD-L1 in patients with CHC, although high levels of sPD-L1 were reported in patients with HCC [@B15]. The expression of PD-L1 in tumor tissues has been reported to be of prognostic value in patients with HCC [@B25]-[@B27]. Finkelmeier *et al.* reported that HCC patients with high serum sPD-L1 concentrations had an increased mortality risk and that high sPD-L1 levels were associated with mortality independently from cirrhosis stage and AFP levels [@B15]. Although no significant correlation between the sPD-L1 levels and platelet counts was found in the present study, we found significant positive correlations between the level of serum sPD-L1 and the levels of AST, ALT and AFP in patients with CHC. This positive correlation between sPD-L1 and AFP levels may suggest an association of sPD-L1 with the generation of HCC, but further investigation would be necessary to confirm that connection.

An increase of sPD-L1 was reported in patients with several malignant diseases, MM [@B17], RCC [@B18], and DLBCL [@B12]. Wang *et al.* reported that patients with MM had higher sPD-L1 concentration than healthy controls, and higher sPD-L1 levels were an independent prognostic factor for shorter progression-free survival [@B17]. In the patients with RCC, higher preoperative sPD-L1 levels were reported to be associated with lager tumors, tumors of advanced stage and grade, and tumors with necrosis [@B18]. Rossille *et al.* reported that among the patients with DLBCL, elevated sPD-L1 was associated with a poorer prognosis, and the sPD-L1 levels dropped back to a normal value after complete remission [@B12]. These reports may suggest that sPD-L1 could outline T-cell inhibitory signals and therefore mirror the anti-immune response of the diseases.

An increase in serum sPD-L1 was also reported in patients with non-malignant diseases such as systemic sclerosis [@B28] and type 2 diabetes mellitus (DM) [@B29]. Yanaba *et al.* reported that serum sPD-L1 levels positively correlated with the severity of skin sclerosis in the patients with systemic sclerosis [@B28]. Shi *et al.* reported that the levels of sPD-L1 in patients with type 2 DM were higher compared with healthy donors and that the increase in sPD-L1 was closely associated with the severity of diabetic atherosclrelotic macorovasucular diseases, especially acute coronary syndrome [@B29]. Therefore, they speculated that sPD-L1 may contribute to continuous T cell activation and development of diabetic macrovascular diseases [@B29]. Abnormal increase of sPD-L1 may intervene in the PD-1/PD-L1 inhibitory pathway and participate in the chronic autoimmune response and pathological progress of inflammation [@B29]. Considering the positive correlation between the sPD-L1 and ALT levels, the increase of sPD-L1 may also contribute to T-cell activation in patients with CHC, which results in an increase in the ALT levels.

We found that the expression of PD-L1 was induced on immortalized hepatocytes by IFN-γ, which was consistent with previous reports that describe how PD-L1was induced in primary human liver cells and hepatoma cells by viral infection and by IFN-α and -γ [@B30]. Mühlbauer *et al.* also reported that the PD-L1 expression on hepatocytes induced apoptosis in T cells by *in vitro* coculture of hepatocytes with T cells, and the authors speculated that the PD-L1 expression in hepatocytes may contribute to hepatic tolerance induction by deletion of activated T cells through the induction of apoptosis [@B30]. Although we did not examine the sPD-L1 in the supernatant of immortalized hepatocytes, Chen *et al.* reported that the existence of sPD-L1 was associated with PD-L1 expressed on the cell surface and that the release of sPD-L1 was, at least in part, associated with matrix metalloproteinase [@B16]. Therefore, we speculated that the increase of sPD-L1 in the patients with CHC might result from the induction of PD-L1 in hepatocytes due to inflammatory cytokines including, IFN-γ.

Although there were no significant differences in the levels of serum ALT between the patients with CHB and CHC, we found that the pretreatment sPD-L1 levels were significantly increased in patients with CHC compared with patients with CHB. The reason the serum sPD-L1 levels differed between patients with CHB and CHC currently remains unclear, but we speculated that a different cytokine profile, mainly the level of IFN-γ, in the liver might result in the difference in the serum sPD-L1 levels between patients with CHB and CHC. Bertoletti *et al.* compared the cytokine profiles of T cell clones derived from the liver infiltrates of patients with CHB and CHC and demonstrated that the predominant T cell population in CHB was represented by T helper (Th) 0 cells producing lower levels of IFN-γ in addition to interleukin (IL)-4 and IL-5. On the other hand, T cells with a Th1-like profile, able to secrete high amounts of IFN-γ, were enriched in the livers of patients with CHC [@B31]. The higher production of IFN-γ in the livers of patients with CHC might account for the release of higher levels of sPD-L1 from hepatocytes compared with patients with CHB. Recently, unexpected early HCC recurrences in patients with HCV-related HCC undergoing IFN-free therapies has been reported [@B32]. Because IFN-γ is mainly produced by natural killer cells and Th1 cells and participates principally in cell-mediated immunity [@B31], such early recurrence might result partly from decreased cell-mediated immunity caused by a decrease in Th1-type cytokine production, including IFN-γ, in the livers of patients with CHC after the eradication of HCV by IFN-free therapies.

The present study has a number of limitations. First, the sample size might have provided inadequate statistical power to detect definitive differences among the patients with CHC, CHB and healthy controls, and between the SVR and no-SVR data in the patients with CHC. Second, we examined only the pretreatment levels of sPD-L1 in patients with CHC. Because we hypothesized that the efficacy of treatments, including IFN, might be more influenced by the sPD-L1 levels in patients with CHC, we enrolled the patients treated with IFN-based treatments in the present study. Although we did not find a significant association between the sPD-L1 levels and the efficacy of treatments, it may be essential to evaluate the influence of treatment on the serum levels of sPD-L1. Third, we examined the serum levels of sPD-L1 in patients with CHC, which was consistent with previous reports [@B15]-[@B18]. However, a recent report showed that sPD-L1 was more detectable in human plasma than in serum [@B12]. Rossille *et al.* speculated that serum might be less efficient for cytokine recovery [@B12]. Therefore, it would be worthwhile to examine sPD-L1 in the plasma of patients with CHC. However, measurements in cohorts of patients with CHB and healthy controls should eliminate this bias.

In conclusion, we first found that sPD-L1 was increased in the sera of patients with CHC, although no association between the sPD-L1 levels and the efficacy of TVR- or SMV-based triple therapy was defined. Our results indicated that the level of serum sPD-L1 might be associated with the progression of CHC and the generation of hepatocellular carcinoma. Although the particular role of sPD-L1 requires further investigation, this study suggested that sPD-L1 might be involved in the immune pathogenesis of CHC.
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![Rates of virological responses to telaprevir and simeprevir. Percentages indicate the proportion of patients with undetectable serum hepatitis C virus (HCV) RNA levels. RVR, rapid virological response; cEVR, complete early virological response; ETR, end of treatment response; SVR, sustained virological response defined as undetectable serum HCV RNA at 24 weeks after the end of treatment. \**P* = 0.001.](ijmsv14p0403g001){#F1}

![Serum sPD-L1 levels in patients with CHC, CHB, and healthy controls. Serum sPD-L1 levels were examined using a specific enzyme-linked immunosorbent assay kit. Pretreatment levels of sPD-L1 in patients with CHC were compared with those in patients with CHB and healthy controls. \**P* \<0.001, \*\**P* = 0.039.](ijmsv14p0403g002){#F2}

![Comparison of pretreatment serum sPD-L1 levels between the patients who achieved SVR and non-SVR. The pretreatment levels of serum sPD-L1 were not significantly different between the patients who achieved SVR and non-SVR (*P* = 0.391). SVR, sustained virological response.](ijmsv14p0403g003){#F4}

![Correlation of serum sPD-L1 levels with asparate aminotransferase (AST) (A), alanine aminotransferase (ALT) (B), platelets (C), and alfa-fetoprotein (AFP) (D) in the patients with CHC. Correlations between the serum sPD-L1 and indicated parameters in patients with CHC were determined by linear regression analysis.](ijmsv14p0403g004){#F3}

![Expression of PD-L1 in immortalized hepatocytes. The expression of PD-L1 on the cell surface of immortalized hepatocytes (HPT1) was examined by flow cytometry before and after stimulation with IFN-γ (A). The expression of PD-L1 mRNA was examined using real-time qPCR before and after stimulation with IFN-γ (B). HLA, human leukocyte antigen.](ijmsv14p0403g005){#F5}

###### 

Patient characteristics

  Factors (Median, range)          Healthy Control    CHB               CHC
  -------------------------------- ------------------ ----------------- --------------------
  n                                10                 22                80
  Gender, n (Male / Female)        5 / 5              11 / 11           41 / 39
  Age (years)                      64 (50-71)         57 (30-76)        63 (28-84)
  Albumin (mg/dL)                  4.3 (3.3-5.0)      4.4 (3.2-4.9)     4.1 (2.8-5.9)
  AST (IU/L)                       21 (16-30)         23 (16-199)       39 (20-200)\*
  ALT (IU/L)                       13 (3-18)          23 (10-336)\*\*   40 (14-316)\*
  Platelets (x10^4^/mm^3^)         18.4 (12.9-22.7)   18.6 (9.9-28.4)   15.6 (7.4-31.7)
  Alpha-fetoprotein (ng/mL)        \-                 3.0 (1.0-9.9)     4.3 (1.1-258.0)^†^
  HCV-RNA (log IU/mL)              \-                 \-                6.7 (4.7-7.8)
  HBV-DNA (log copies/mL)          \-                 4.5 (0-8.6)       \-
  Nucleoside analogue, n (- / +)   \-                 19 / 3            \-

CHB, chronic hepatitis B; CHC chronic hepatitis C; AST, asparate aminotransferase; ALT, alanine aminotransferase; HCV, hepatitis C virus; HBV, hepatitis B virus. \**P* \<0.01 (compared with HC), \*\**P* \<0.05 (compared with HC), ^†^*P* \<0.05 (compared with CHB).

###### 

Patient characteristics (CHC)

  Factors (Median, range)                                         Telaprevir          Simeprevir          *P* value
  --------------------------------------------------------------- ------------------- ------------------- -----------
  n                                                               40                  40                  \-
  Gender, n (Male / Female)                                       23 / 17             18 / 22             0.371
  Age (years)                                                     62 (28-77)          65 (36-84)          0.253
  Body weight (kg)                                                59.2 (40.0-97.4)    58.6 (37.5-83.7)    0.593
  Body mass index (kg/m^2^)                                       23.0 (15.8-32.2)    22.8 (17.8-28.6)    0.951
  Baseline HCV-RNA (log IU/mL)                                    6.7 (5.4-7.8)       6.7 (4.7-7.8)       0.129
  White blood cell (/mm^3^)                                       5150 (1900-8400)    4525 (2600-7500)    0.112
  Hemoglobin (g/dL)                                               14.2 (10.9-18.6)    13.5 (10.0-16.7)    0.034
  Platelets (x10^4^/mm^3^)                                        14.9 (7.4-24.0)     16.3 (8.7-31.7)     0.080
  Albumin (mg/dL)                                                 4.1 (3.4-5.9)       4.1 (2.8-4.8)       0.899
  AST (IU/L)                                                      40 (17-249)         38 (20-159)         0.221
  ALT (IU/L)                                                      40 (18-278)         41 (14-316)         0.362
  GGT (IU/L)                                                      31 (11-418)         27 (9-260)          0.394
  Serum creatinine (mg/dL)                                        0.74 (0.36-1.16)    0.69 (0.43-1.36)    0.181
  Estimated GFR (mL/min)                                          77.0 (44.0-134.0)   80.5 (41.3-112.6)   0.912
  Alpha-fetoprotein (ng/mL)                                       4.4 (1.1-144.9)     4.1 (1.2-258.0)     0.768
  Prior treatment response, n (naïve / relapse / non-responder)   19 / 17 / 4         21 / 13 / 6         0.574
  IL28B SNP (rs8099917), n (TT / non-TT / ND)                     24 / 15 / 1         24 / 14 / 2         1

AST, asparate aminotransferase; ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; GFR, glomerular filtration rate; IL28B SNP, interleukin-28B single nucleotide polymorphism; ND, not determined.

###### 

Treatment tolerability

                                        Telaprevir         Simeprevir         *P* value
  ------------------------------------- ------------------ ------------------ -----------
  n                                     40                 40                 \-
  Initial doses (Median, range)                                               
  PegIFN-α2a / BW (μg/kg/week)                             3.10 (2.15-4.25)   \-
  PegIFN-α2b / BW (μg/kg/week)          1.50 (0.92-2.00)   1.51 (1.19-2.67)   0.070
  TVR / BW (mg/kg/day)                  31.4 (17.3-56.3)   \-                 \-
  SMV / BW (mg/kg/day)                  \-                 1.71 (1.19-2.67)   \-
  RBV / BW (mg/kg/day)                  11.6 (6.9-20.0)    11.6 (6.0-16.8)    0.749
  Dose reduction / Discontinuation, n                                         
  PegIFN-α                              2 / 6              3 / 5              1
  TVR / SMV                             11 / 8             0 / 1              \<0.001
  RBV                                   24 / 6             15 / 4             0.039
  Adherence, mean ± SD (%)                                                    
  PegIFN-α                              92.1 ± 21.2        98.5 ± 26.4        0.235
  TVR / SMV                             88.7 ± 22.0        95.3 ± 22.5        0.188
  RBV                                   75.9 ± 24.7        92.1 ± 28.0        0.007

PegIFN, pegylated-interferon; BW, body weight; TVR, telaprevir; SMV, simeprevir; RBV, ribavirin.
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